List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4995707/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guideline Development for Medical Device Technology: Issues for Consideration. Journal of Diabetes Science and Technology, 2023, 17, 1698-1710.	2.2	2
2	Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. European Journal of Preventive Cardiology, 2022, 29, 383-395.	1.8	40
3	Association of high cardiovascular risk and diabetes with calcified carotid artery atheromas depicted on panoramic radiographs. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2022, 133, 88-99.	0.4	2
4	Endodontic inflammatory disease: A risk indicator for a first myocardial infarction. International Endodontic Journal, 2022, 55, 6-17.	5.0	12
5	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. European Journal of Preventive Cardiology, 2022, 29, 328-339.	1.8	27
6	Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry. European Journal of Preventive Cardiology, 2022, 29, 344-351.	1.8	22
7	Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test. Diabetes Research and Clinical Practice, 2022, 183, 109156.	2.8	1
8	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	3.0	6
9	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50.	6.8	8
10	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3448-e3454.	3.6	2
11	Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population. Diabetes Care, 2022, 45, 2111-2117.	8.6	4
12	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	2.2	17
13	Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry. Cardiovascular Drugs and Therapy, 2021, 35, 801-808.	2.6	9
14	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. European Journal of Preventive Cardiology, 2021, 28, 370-379.	1.8	83
15	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. International Journal of Cardiology, 2021, 322, 227-232.	1.7	9
16	Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. Cardiovascular Diabetology, 2021, 20, 38.	6.8	17
17	Copeptin is associated with mortality in elderly people. European Journal of Clinical Investigation, 2021, 51, e13516.	3.4	6
18	Applying <scp>REWIND</scp> cardiovascular disease criteria to <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6: An exploratory analysis of cardiovascular outcomes with semaglutide. Diabetes, Obesity and Metabolism, 2021, 23, 1677-1680.	4.4	4

#	Article	IF	CITATIONS
19	Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. Diabetes and Vascular Disease Research, 2021, 18, 147916412110024.	2.0	6
20	Heart failure at the crossroads of cardiology and diabetology. Diabetes Research and Clinical Practice, 2021, 175, 108844.	2.8	0
21	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. Diabetes Research and Clinical Practice, 2021, 175, 108796.	2.8	11
22	The history of the Nobel prize for the discovery of insulin. Diabetes Research and Clinical Practice, 2021, 175, 108819.	2.8	12
23	Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	4.0	5
24	Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs, 2021, 81, 1373-1379.	10.9	13
25	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Research and Clinical Practice, 2021, 177, 108870.	2.8	4
26	Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction. European Heart Journal Open, 2021, 1, .	2.3	0
27	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 484-490.	11.4	17
28	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions. Current Cardiology Reports, 2021, 23, 136.	2.9	5
29	ls cardioprotection with GLP-1 receptor agonists a class effect?. European Journal of Preventive Cardiology, 2021, 28, 18-21.	1.8	0
30	Is the impact of add on heart failure therapy influenced by background therapy?. Lancet Diabetes and Endocrinology,the, 2021, , .	11.4	0
31	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. European Journal of Preventive Cardiology, 2020, 27, 1630-1636.	1.8	23
32	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
33	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 106-114.	11.4	77
34	ls Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management. Diabetes Care, 2020, 43, 2001-2009.	8.6	12
35	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, 199.	6.8	14
36	Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care, 2020, 43, 2853-2858.	8.6	15

#	Article	IF	CITATIONS
37	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. Diabetes Research and Clinical Practice, 2020, 170, 108488.	2.8	4
38	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	10.2	123
39	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. Diabetes and Vascular Disease Research, 2020, 17, 147916412092212.	2.0	1
40	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation, 2020, 141, 1841-1854.	1.6	96
41	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes Care, 2020, 43, 2242-2247.	8.6	11
42	Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease—A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Diabetes Care, 2020, 43, 726-733.	8.6	46
43	Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504–1511. Diabetes Care, 2020, 43, e9-e9.	8.6	0
44	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation, 2019, 140, 1451-1459.	1.6	36
45	The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients. American Journal of Medicine, 2019, 132, 921-925.	1.5	15
46	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	13.7	1,625
47	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	13.7	394
48	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care, 2019, 42, 1504-1511.	8.6	16
49	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis, 2019, 285, 135-146.	0.8	227
50	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
51	Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. European Journal of Preventive Cardiology, 2019, 26, 25-32.	1.8	365
52	Risk factor reduction in type 2 diabetes demands a multifactorial approach. European Journal of Preventive Cardiology, 2019, 26, 81-91.	1.8	13
53	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. European Journal of Preventive Cardiology, 2019, 26, 73-80.	1.8	56
54	The metabolic syndrome – What is it and how should it be managed?. European Journal of Preventive Cardiology, 2019, 26, 33-46.	1.8	130

#	Article	IF	CITATIONS
55	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. European Heart Journal, 2019, 40, 2907-2919.	2.2	32
56	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. European Journal of Preventive Cardiology, 2019, 26, 847-854.	1.8	11
57	Attitudes and lifestyle factors in relation to oral health and dental care in Sweden: a cross-sectional study. Acta Odontologica Scandinavica, 2019, 77, 282-289.	1.6	7
58	Antiphospholipid Antibodies in Patients With Myocardial Infarction. Annals of Internal Medicine, 2019, 170, 277.	3.9	17
59	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. European Journal of Epidemiology, 2019, 34, 247-258.	5.7	22
60	A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. Global Heart, 2019, 14, 215.	2.3	24
61	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. Circulation, 2018, 137, 88-90.	1.6	30
62	Effects of enhanced external counterpulsation on skeletal muscle gene expression in patients with severe heart failure. Clinical Physiology and Functional Imaging, 2018, 38, 118-127.	1.2	3
63	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diabetes and Vascular Disease Research, 2018, 15, 14-23.	2.0	18
64	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 2018, 199, 170-175.	2.7	5
65	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	13.7	651
66	Effectiveness of different outreach strategies to identify individuals at high risk of diabetes in a heterogeneous population: a study in the Swedish municipality of SödertÃ ÿ e. European Journal of Preventive Cardiology, 2018, 25, 1990-1999.	1.8	5
67	Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data. Clinical Science, 2018, 132, 2003-2012.	4.3	10
68	The Accuracy of Point-of-Care Equipment for Glucose Measurement in Screening for Dysglycemia in Patients with Coronary Artery Disease. Diabetes Technology and Therapeutics, 2018, 20, 596-602.	4.4	8
69	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diabetes and Vascular Disease Research, 2018, 15, 494-503.	2.0	37
70	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. International Journal of Cardiology, 2018, 272, 20-25.	1.7	24
71	Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort. Diabetes and Vascular Disease Research, 2018, 15, 387-395.	2.0	6
72	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2522-2533.	3.6	7

#	Article	IF	CITATIONS
73	Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2018, 17, 21.	6.8	15
74	On the prognostic value of post-load glucose in patients with coronary artery disease. European Heart Journal, 2018, 39, 2746-2748.	2.2	10
75	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care, 2018, 41, 1792-1800.	8.6	25
76	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2017, 5, 391-402.	11.4	56
77	Symptoms of depression and their relation to myocardial infarction and periodontitis. European Journal of Cardiovascular Nursing, 2017, 16, 468-474.	0.9	17
78	The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial. European Journal of Preventive Cardiology, 2017, 24, 858-866.	1.8	33
79	New Hope For People With Dysglycemia and Cardiovascular Disease Manifestations. Circulation, 2017, 135, 1894-1896.	1.6	6
80	Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of Cardiology. European Journal of Preventive Cardiology, 2017, 24, 1168-1180.	1.8	13
81	Saliva and plasma levels of cardiacâ€related biomarkers in postâ€myocardial infarction patients. Journal of Clinical Periodontology, 2017, 44, 692-699.	4.9	10
82	The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV. Diabetes Care, 2017, 40, 1233-1240.	8.6	83
83	Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure. Lancet Diabetes and Endocrinology,the, 2017, 5, 325-326.	11.4	6
84	Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diabetes and Vascular Disease Research, 2017, 14, 77-87.	2.0	19
85	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
86	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	11.4	245
87	Updates on cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2017, 16, 128.	6.8	45
88	Anaemia and iron deficiency in heart failure: epidemiological gaps, diagnostic challenges and therapeutic barriers in sub-Saharan Africa. Cardiovascular Journal of Africa, 2017, 28, 331-337.	0.4	0
89	Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999–2013. Global Heart, 2017, 12, 315.	2.3	81
90	Response by Rydén to Letter Regarding Article, "Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study― Circulation, 2016, 134, e2.	1.6	2

#	Article	IF	CITATIONS
91	Periodontal disease – important to consider in cardiovascular disease prevention. Expert Review of Cardiovascular Therapy, 2016, 14, 987-989.	1.5	18
92	Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV. BMJ Open, 2016, 6, e013835.	1.9	6
93	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. European Journal of Preventive Cardiology, 2016, 23, 1618-1627.	1.8	19
94	Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG. Clinical Therapeutics, 2016, 38, 1279-1287.	2.5	18
95	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). International Journal of Cardiology, 2016, 220, 750-758.	1.7	13
96	Current perspectives on cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2016, 15, 139.	6.8	59
97	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. European lournal of Preventive Cardiology, 2016, 23, 2007-2018.	1.8	153
98	Prognostic Implications of TypeÂ2ÂDiabetesÂMellitus in IschemicÂandÂNonischemic Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1404-1416.	2.8	77
99	Oral glucose tolerance testing and cardiovascular disease. Lancet Diabetes and Endocrinology,the, 2016, 4, 732-733.	11.4	5
100	Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study. Diabetes and Vascular Disease Research, 2016, 13, 307-311.	2.0	6
101	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683
102	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648.	1.8	772
103	Periodontitis Increases the Risk of a First Myocardial Infarction. Circulation, 2016, 133, 576-583.	1.6	200
104	Treatment of diabetes and heart failure: joint forces. European Heart Journal, 2016, 37, 1535.2-1537.	2.2	12
105	Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to) Tj ETQq1	ኴጩ7 843]	1 4 3gBT /O∨
106	Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diabetes and Vascular Disease Research, 2015, 12, 23-32.	2.0	49
107	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2015, 14, 133.	6.8	101
108	Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. Heart, 2015, 101, 592-599.	2.9	23

#	Article	IF	CITATIONS
109	Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology. European Heart Journal, 2015, 36, 1171-1177.	2.2	81
110	Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. Heart, 2015, 101, 1139-1148.	2.9	36
111	Accuracy of a Simplified Glucose Measurement Device—The HemoCue Glucose 201RT. Diabetes Technology and Therapeutics, 2015, 17, 755-758.	4.4	16
112	Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study. European Journal of Preventive Cardiology, 2015, 22, 753-761.	1.8	25
113	Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 1515.	7.4	206
114	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. Diabetes and Vascular Disease Research, 2014, 11, 395-409.	2.0	15
115	The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. Diabetes and Vascular Disease Research, 2014, 11, 290-293.	2.0	13
116	Detection of Circulating hcmv-miR-UL112-3p in Patients with Glioblastoma, Rheumatoid Arthritis, Diabetes Mellitus and Healthy Controls. PLoS ONE, 2014, 9, e113740.	2.5	29
117	Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. Heart, 2014, 100, 1235-1241.	2.9	93
118	Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 627-633.	11.4	73
119	GuÃa de práctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
120	Longitudinal Development of Left Ventricular Diastolic Function in Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 3092-3097.	8.6	13
121	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal, 2014, 168, 23-29.e2.	2.7	50
122	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758
123	Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes. European Journal of Preventive Cardiology, 2013, 20, 549-554.	1.8	24
124	Self-rated health predicts outcome in patients with type 2 diabetes and myocardial infarction: A DIGAMI 2 quality of life sub-study. Diabetes and Vascular Disease Research, 2013, 10, 361-367.	2.0	19
125	Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: A DIGAMI2 QoL sub-study. Diabetes and Vascular Disease Research, 2013, 10, 263-269.	2.0	6
126	Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes. Journal of Hypertension, 2013, 31, 414-421.	0.5	72

#	Article	IF	CITATIONS
127	Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: A report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study. Diabetes and Vascular Disease Research, 2012, 9, 287-295.	2.0	12
128	Mortality prediction in the elderly by an easily measured metabolic index. Diabetes and Vascular Disease Research, 2012, 9, 226-233.	2.0	2
129	Joint ESC/EASD Guidelines on Diabetes, where are we Now and where should we Go?. Current Vascular Pharmacology, 2012, 10, 690-692.	1.7	3
130	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.8	414
131	Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention	2.2	5,247
132	Glucose perturbation (EACPR). European Hear Journal, 2012, 33, 1635-1701. Glucose perturbations and cardiovascular risk: Challenges and opportunities. Diabetes and Vascular Disease Research, 2012, 9, 170-176.	2.0	19
133	The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2011, 8, 143-149.	2.0	2
134	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124, 1727-1736.	1.6	156
135	Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. Reviews in Endocrine and Metabolic Disorders, 2010, 11, 87-94.	5.7	9
136	Diabetes, prediabetes and cardiovascular risk. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, s9-s14.	2.8	51
137	Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on Diabetes and the Heart. European Heart Journal, 2010, 31, 3040-3045.	2.2	48
138	The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction. International Journal of Cardiology, 2010, 145, 259-260.	1.7	13
139	Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 8-9.	2.8	1
140	Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. Diabetes and Vascular Disease Research, 2009, 6, 71-79.	2.0	20
141	A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. European Journal of Heart Failure, 2009, 11, 39-47.	7.1	65
142	A gluco-metabolic risk index with cardiovascular risk stratification potential in patients with coronary artery disease. Diabetes and Vascular Disease Research, 2009, 6, 62-70.	2.0	9
143	Cardiovascular Prevention in Patients with Diabetes and Prediabetes. Herz, 2008, 33, 170-177.	1.1	16

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq0 0 0 rgBT /Overloak 10 Tf 144

#	Article	IF	CITATIONS
145	Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes. European Journal of Heart Failure, 2008, 10, 1080-1087.	7.1	50
146	Oral Glucose Tolerance Test: A Reliable Tool for Early Detection of Glucose Abnormalities in Patients With Acute Myocardial Infarction in Clinical Practice: A report on repeated oral glucose tolerance tests from the GAMI Study. Diabetes Care, 2008, 31, 36-38.	8.6	86
147	Implications of abnormal glucose metabolism in patients with coronary artery disease. Diabetes and Vascular Disease Research, 2008, 5, 285-290.	2.0	19
148	Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. European Heart Journal, 2008, 29, 1753-1760.	2.2	87
149	Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 216-223.	2.8	73
150	What are the risk factors for progression of coronary artery calcification in patients with type 2 diabetes?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 370-371.	3.3	3
151	The management of the type 2 diabetic patient with hypertension – too late and too little: Suggested improvements. Blood Pressure, 2008, 17, 250-259.	1.5	7
152	Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. European Heart Journal, 2007, 29, 177-184.	2.2	99
153	Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. European Heart Journal, 2007, 28, 1402-1402.	2.2	392
154	The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. European Heart Journal, 2007, 29, 166-176.	2.2	149
155	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1	1 02.78 8431	.4 ஜBT /Ove
156	Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 28-36.	2.8	48
157	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1	1 0. 88431	14 3gB T /Ove
158	Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary. Revista Espanola De Cardiologia (English Ed), 2007, 60, 525.	0.6	11
159	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	2.2	1,144
160	Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. European Heart Journal, 2006, 27, 2969-2974.	2.2	150
161	Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart, 2006, 93, 1577-1583.	2.9	131
162	Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 465-471.	2.8	43

#	Article	IF	CITATIONS
163	The Association Between Glucose Abnormalities and Heart Failure in the Population-Based Reykjavik Study. Diabetes Care, 2005, 28, 612-616.	8.6	269
164	Patient access to medical technology across Europe. European Heart Journal, 2004, 25, 611-616.	2.2	26
165	The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. European Heart Journal, 2004, 25, 1880-1890.	2.2	532
166	Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology, 2004, 43, 585-591.	2.8	267
167	Effects of Trimetazidine on Left Ventricular Function in Patients with Type 2 Diabetes and Heart Failure. Journal of Cardiovascular Pharmacology, 2004, 44, 101-108.	1.9	40
168	Diabetes, Insulin Resistance, and the Metabolic Syndrome in Patients With Acute Myocardial Infarction Without Previously Known Diabetes. Diabetes Care, 2003, 26, 2770-2776.	8.6	112
169	Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, The, 2002, 359, 2140-2144.	13.7	968
170	Arne Larsson 1915-2001. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 521-521.	1.2	0
171	Reduction of hospital days by biventricular pacing. European Journal of Heart Failure, 2000, 2, 399-406.	7.1	54
172	Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death. Circulation, 2000, 102, 611-616.	1.6	298
173	Ramipril reduced mortality and cardiovascular morbidity in high-risk adults. ACP Journal Club, 2000, 132, 41.	0.1	0
174	The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovascular Drugs and Therapy, 1999, 13, 347-354.	2.6	10
175	Coronary venous drug infusion in the ischaemic-reperfused isolated rat heart. Cardiovascular Research, 1996, 31, 82-92.	3.8	2
176	Pacing in Dilated Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 1341-1345.	1.2	2
177	Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. Journal of the American College of Cardiology, 1995, 26, 57-65.	2.8	1,450
178	Quality-of-Life in Patients Treated with Atrioventricular Synchronous Pacing Compared to Rate Modulated Ventricular Pacing: A Long-Term, Double-Blind, Crossover Study. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1467-1476.	1.2	78
179	A Double-Blind Study of Submaximal Exercise Tolerance and Variation in Paced Rate in Atrial Synchronous Compared to Activity Sensor Modulated Ventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 905-915.	1.2	32
180	Holter Documented Sudden Death in a Patient with an Implanted Defibrillator. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1008-1014.	1.2	49

#	Article	IF	CITATIONS
181	Longevity in Patients With High Degree Atrioventricular Block Paced in the Atrial Synchronous or the Fixed Rate Ventricular Inhibited Mode. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 304-313.	1.2	53
182	Longâ€Term Cardiovascular Effects of Metoprolol Therapy: A Review Article. Journal of Clinical Pharmacology, 1990, 30, S118-23.	2.0	7
183	Metoprolol CR/ZOK. Journal of Clinical Pharmacology, 1990, 30, S1-S1.	2.0	0
184	Efficacy of Epanolol versus Metoprolol in Angina Pectoris Results from the Swedish Multicenter Study of Exercise Tolerance. Drugs, 1989, 38, 66.	10.9	0
185	Obituary Joep Perk. European Heart Journal, 0, , .	2.2	0